Literature DB >> 28581347

Questioning Our APHINITY for More.

Kathy D Miller1.   

Abstract

Year:  2017        PMID： 28581347     DOI： 10.1056/NEJMe1706150

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others".

Authors:  B Basulaiman; A Awan; J F Hilton; M Clemons
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

2.  Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.

Authors:  Pat W Whitworth; Peter D Beitsch; Mary K Murray; Paul D Richards; Angela Mislowsky; Carrie L Dul; James V Pellicane; Paul L Baron; Rakhshanda Layeequr Rahman; Laura A Lee; Beth B Dupree; Pond R Kelemen; Andrew Y Ashikari; Raye J Budway; Cristina Lopez-Penalver; William Dooley; Shiyu Wang; Patricia Dauer; Andrea R Menicucci; Erin B Yoder; Christine Finn; Lisa E Blumencranz; William Audeh
Journal:  JCO Precis Oncol       Date:  2022-09

Review 3.  Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer.

Authors:  Alexander Ring; Maria Spataro; Andreas Wicki; Nicola Aceto
Journal:  Front Cell Dev Biol       Date:  2022-06-28

4.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Authors:  Helena M Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Adrian N Harnett; Mei-Lin Ah-See; Richard Simcock; Daniel Rea; Sanjay Raj; Pamela Woodings; Mark Harries; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Janine Mansi; Ioannis Gounaris; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Jean E Abraham; Carlos Caldas; Peter S Hall; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn
Journal:  Lancet       Date:  2019-06-06       Impact factor: 79.321

Review 5.  Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.

Authors:  Mariko Asaoka; Shipra Gandhi; Takashi Ishikawa; Kazuaki Takabe
Journal:  Breast Cancer (Auckl)       Date:  2020-12-16

Review 6.  Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.

Authors:  Pashtoon M Kasi; Gordon Fehringer; Hiroya Taniguchi; Naureen Starling; Yoshiaki Nakamura; Daisuke Kotani; Thomas Powles; Bob T Li; Lajos Pusztai; Vasily N Aushev; Ekaterina Kalashnikova; Shruti Sharma; Meenakshi Malhotra; Zachary P Demko; Alexey Aleshin; Angel Rodriguez; Paul R Billings; Axel Grothey; Julien Taieb; David Cunningham; Takayuki Yoshino; Scott Kopetz
Journal:  JCO Precis Oncol       Date:  2022-03

Review 7.  Progress in adjuvant systemic therapy for breast cancer.

Authors:  Noam F Pondé; Dimitrios Zardavas; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

8.  Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Authors:  Robert Kemp; Vinay Prasad
Journal:  BMC Med       Date:  2017-07-21       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.